S&P 500   3,852.36
DOW   32,920.46
QQQ   293.34
Mullen Automotive: The Good News, The Bad And The Ugly Outlook 
Hot craft spirits opportunity you don't want to miss (Ad)pixel
A Non-Salesy Annuity Guide To Buying Annuities
3 Small Caps That Have Big Upside
The Next Big Crisis Is Here (Ad)
Levi Strauss Is A Good Fit For Income Investors 
What Does Apple's Move to India Mean for Investors?
Hot craft spirits opportunity you don't want to miss (Ad)pixel
Mergers and Acquisitions in 2023 Off To A Strong Start
Chevron Delights Shareholders with $75 Billion in Share Buybacks
S&P 500   3,852.36
DOW   32,920.46
QQQ   293.34
Mullen Automotive: The Good News, The Bad And The Ugly Outlook 
Hot craft spirits opportunity you don't want to miss (Ad)pixel
A Non-Salesy Annuity Guide To Buying Annuities
3 Small Caps That Have Big Upside
The Next Big Crisis Is Here (Ad)
Levi Strauss Is A Good Fit For Income Investors 
What Does Apple's Move to India Mean for Investors?
Hot craft spirits opportunity you don't want to miss (Ad)pixel
Mergers and Acquisitions in 2023 Off To A Strong Start
Chevron Delights Shareholders with $75 Billion in Share Buybacks
S&P 500   3,852.36
DOW   32,920.46
QQQ   293.34
Mullen Automotive: The Good News, The Bad And The Ugly Outlook 
Hot craft spirits opportunity you don't want to miss (Ad)pixel
A Non-Salesy Annuity Guide To Buying Annuities
3 Small Caps That Have Big Upside
The Next Big Crisis Is Here (Ad)
Levi Strauss Is A Good Fit For Income Investors 
What Does Apple's Move to India Mean for Investors?
Hot craft spirits opportunity you don't want to miss (Ad)pixel
Mergers and Acquisitions in 2023 Off To A Strong Start
Chevron Delights Shareholders with $75 Billion in Share Buybacks
S&P 500   3,852.36
DOW   32,920.46
QQQ   293.34
Mullen Automotive: The Good News, The Bad And The Ugly Outlook 
Hot craft spirits opportunity you don't want to miss (Ad)pixel
A Non-Salesy Annuity Guide To Buying Annuities
3 Small Caps That Have Big Upside
The Next Big Crisis Is Here (Ad)
Levi Strauss Is A Good Fit For Income Investors 
What Does Apple's Move to India Mean for Investors?
Hot craft spirits opportunity you don't want to miss (Ad)pixel
Mergers and Acquisitions in 2023 Off To A Strong Start
Chevron Delights Shareholders with $75 Billion in Share Buybacks

Editas Medicine - EDIT Stock Forecast, Price & News

$9.07
-0.02 (-0.22%)
(As of 01/26/2023 12:00 AM ET)
Add
Compare
Today's Range
$8.74
$9.30
50-Day Range
$7.81
$10.95
52-Week Range
$7.70
$21.59
Volume
1.73 million shs
Average Volume
2.00 million shs
Market Capitalization
$623.68 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$16.86

Editas Medicine MarketRank™ Forecast

Analyst Rating
Hold
2.14 Rating Score
Upside/​Downside
85.9% Upside
$16.86 Price Target
Short Interest
Bearish
32.20% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.84
Upright™ Environmental Score
News Sentiment
0.60mentions of Editas Medicine in the last 14 days
Based on 16 Articles This Week
Insider Trading
Selling Shares
$17,481 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($3.15) to ($2.97) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.32 out of 5 stars

Medical Sector

291st out of 1,048 stocks

Biological Products, Except Diagnostic Industry

45th out of 168 stocks


EDIT stock logo

About Editas Medicine (NASDAQ:EDIT) Stock

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads to inherited childhood blindness. It also develops EDIT-102 for the treatment of Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss; autosomal dominant retinitis pigmentosa, a progressive form of retinal degeneration; and EDIT-301 to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing gene-edited Natural Killer cell medicines to treat solid tumor cancers; alpha-beta T cells for multiple cancers; and gamma delta T cell therapies to treat cancer, as well as has an early discovery program to develop a therapy to treat a neurological disease. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders; and research collaboration with Asklepios BioPharmaceutical, Inc. to develop a therapy to treat a neurological disease, as well as research collaboration with AskBio. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

Receive EDIT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Editas Medicine and its competitors with MarketBeat's FREE daily newsletter.

EDIT Stock News Headlines

How Will Early 2023 Layoffs Affect These 5 Biotech Stocks? (EDIT)
Five biotechs have already issued layoffs in 2023. Many seem to have good potential, but time will tell if the shifts create the value analysts anticipate.
Hot craft spirits opportunity you don't want to miss
Award winning products. Global distribution. New distillery. New products.pixel
Editas Medicine (NASDAQ:EDIT) Price Target Cut to $7.00
Editas Medicine (NASDAQ:EDIT) PT Raised to $7.00 at SVB Leerink
Hot craft spirits opportunity you don't want to miss
Award winning products. Global distribution. New distillery. New products.pixel
Analyst Expectations for Editas Medicine's Future
Here's Why Editas (EDIT) Looks Ripe for Bottom Fishing
Why Editas Medicine's Shares Are Falling Thursday
See More Headlines
Receive EDIT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Editas Medicine and its competitors with MarketBeat's FREE daily newsletter.

EDIT Company Calendar

Last Earnings
11/02/2022
Today
1/26/2023
Next Earnings (Estimated)
2/23/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:EDIT
Fax
N/A
Employees
264
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$16.86
High Stock Price Forecast
$36.00
Low Stock Price Forecast
$7.00
Forecasted Upside/Downside
+85.9%
Consensus Rating
Hold
Rating Score (0-4)
2.14
Research Coverage
14 Analysts

Profitability

Net Income
$-192,500,000.00
Net Margins
-784.32%
Pretax Margin
-784.32%

Debt

Sales & Book Value

Annual Sales
$25.54 million
Book Value
$8.09 per share

Miscellaneous

Free Float
67,869,000
Market Cap
$623.68 million
Optionable
Optionable
Beta
1.90

Key Executives

  • Mr. James C. MullenMr. James C. Mullen (Age 64)
    Exec. Chairman
    Comp: $1.01M
  • Ms. Michelle  RobertsonMs. Michelle Robertson (Age 56)
    CFO, Principal Accounting Officer, Treasurer & Assistant Sec.
    Comp: $641.74k
  • Dr. Mark S. Shearman (Age 63)
    Exec. VP & Chief Scientific Officer
    Comp: $639.89k
  • Dr. Bruce E. Eaton Ph.D. (Age 69)
    Exec. VP & Chief Bus. Officer
    Comp: $1.09M
  • Dr. Gilmore O'Neill (Age 59)
    Pres & CEO
  • Dr. Feng Zhang Ph.D.
    Co-Founder & Scientific Advisory Board Member
  • Dr. George McDonald Church Ph.D. (Age 69)
    Co-Founder & Scientific Advisory Board Member
  • Dr. J. Keith Joung M.D.
    Ph.D., Co-Founder & Scientific Advisory Board Member
  • Dr. David R. Liu Ph.D.
    Co-Founder & Scientific Advisory Board Member
  • Mr. Harry R. Gill III (Age 62)
    Sr. VP of Operations













EDIT Stock - Frequently Asked Questions

Should I buy or sell Editas Medicine stock right now?

14 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Editas Medicine in the last year. There are currently 2 sell ratings, 8 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" EDIT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in EDIT, but not buy additional shares or sell existing shares.
View EDIT analyst ratings
or view top-rated stocks.

What is Editas Medicine's stock price forecast for 2023?

14 brokerages have issued 12-month price objectives for Editas Medicine's stock. Their EDIT share price forecasts range from $7.00 to $36.00. On average, they expect the company's stock price to reach $16.86 in the next twelve months. This suggests a possible upside of 85.9% from the stock's current price.
View analysts price targets for EDIT
or view top-rated stocks among Wall Street analysts.

How have EDIT shares performed in 2023?

Editas Medicine's stock was trading at $8.87 at the beginning of 2023. Since then, EDIT shares have increased by 2.3% and is now trading at $9.07.
View the best growth stocks for 2023 here
.

When is Editas Medicine's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023.
View our EDIT earnings forecast
.

How were Editas Medicine's earnings last quarter?

Editas Medicine, Inc. (NASDAQ:EDIT) posted its quarterly earnings results on Wednesday, November, 2nd. The company reported ($0.81) earnings per share for the quarter, topping the consensus estimate of ($0.87) by $0.06. The business had revenue of $0.04 million for the quarter, compared to analyst estimates of $5.86 million. Editas Medicine had a negative net margin of 784.32% and a negative trailing twelve-month return on equity of 41.33%.

What other stocks do shareholders of Editas Medicine own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Editas Medicine investors own include CRISPR Therapeutics (CRSP), NVIDIA (NVDA), Micron Technology (MU), Intellia Therapeutics (NTLA), Block (SQ), Advanced Micro Devices (AMD), Alibaba Group (BABA), QUALCOMM (QCOM), Cisco Systems (CSCO) and Skyworks Solutions (SWKS).

When did Editas Medicine IPO?

(EDIT) raised $100 million in an initial public offering on Wednesday, February 3rd 2016. The company issued 5,900,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley and J.P. Morgan acted as the underwriters for the IPO and Cowen and Company and JMP Securities were co-managers.

What is Editas Medicine's stock symbol?

Editas Medicine trades on the NASDAQ under the ticker symbol "EDIT."

Who are Editas Medicine's major shareholders?

Editas Medicine's stock is owned by a number of institutional and retail investors. Top institutional investors include Exchange Traded Concepts LLC (0.13%), Green Alpha Advisors LLC (0.09%), McGuire Investment Group LLC (0.02%), Elmwood Wealth Management Inc. (0.02%) and Sigma Planning Corp (0.02%). Insiders that own company stock include Bruce Eaton, Charles Albright, Cynthia Collins, James C Mullen, Lisa Anne Michaels, Mark S Shearman and Michelle Robertson.
View institutional ownership trends
.

How do I buy shares of Editas Medicine?

Shares of EDIT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Editas Medicine's stock price today?

One share of EDIT stock can currently be purchased for approximately $9.07.

How much money does Editas Medicine make?

Editas Medicine (NASDAQ:EDIT) has a market capitalization of $623.68 million and generates $25.54 million in revenue each year. The company earns $-192,500,000.00 in net income (profit) each year or ($2.94) on an earnings per share basis.

How many employees does Editas Medicine have?

The company employs 264 workers across the globe.

How can I contact Editas Medicine?

Editas Medicine's mailing address is 11 Hurley Street, Cambridge MA, 02141. The official website for the company is www.editasmedicine.com. The company can be reached via phone at (617) 401-9000 or via email at mark.mullikin@editasmed.com.

This page (NASDAQ:EDIT) was last updated on 1/27/2023 by MarketBeat.com Staff